Host DNA: A Window Into Gut Lining Turnover

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

The Host DNA test measures how much human genetic material -- shed from your own intestinal lining and immune cells -- is present in a stool sample, reported as a proportion of total DNA. Because the gut continuously renews its lining, small amounts are expected, while higher levels are associated with increased epithelial turnover or inflammation. It also helps confirm a sample is adequate, and may add context to the rest of your gut-microbiome results.

Read more →

Understand what your gut health results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

A direct window into gut lining turnover

A host DNA test measures the amount of human genetic material, shed from your own intestinal lining and immune cells, present in a stool sample. In practice, the lab quantifies human DNA using methods such as quantitative PCR or by mapping reads in sequencing data to the human genome. Results are typically reported as a proportion of total DNA (human vs. microbial) or as an absolute signal per gram of stool. Because the gut continuously renews its lining, small amounts of host DNA are expected; higher levels can indicate increased epithelial turnover or inflammation. This measurement also helps confirm that a sample is adequate and not overly diluted.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

What the signal actually tells you

Why it matters: host DNA offers a direct window into gut barrier activity. The intestinal lining is a dynamic interface where cells absorb nutrients, interact with microbes, and regulate immune responses. When the barrier is calm and intact, cellular shedding stays relatively steady. When irritated by infection, inflammatory conditions, medications, or extreme stress, shedding can rise. Interpreted alongside symptoms and other biomarkers, host DNA helps translate biology into signals about gut integrity, immune activation, and sample quality. Although methods differ across labs, the underlying principle remains consistent: human DNA in stool reflects the state of the host, not just the microbes.

In real life, the line between “just a stomach bug” and “something that needs attention” can feel blurry. Host DNA testing adds context. Elevated human DNA in stool can align with mucosal inflammation or injury, which often accompanies symptoms like watery diarrhea, urgency, or abdominal pain. It can also help clarify the after-effects of an acute infection, a course of antibiotics, or frequent NSAID use during marathon training. For people monitoring known GI conditions with their clinicians, host DNA complements validated stool markers by highlighting epithelial shedding patterns during flares and recoveries.

Zooming out, gut barrier health influences systemic inflammation, nutrient handling, and immune tone. Tracking host DNA across time reveals patterns — for example, whether your lining settles after a stressful month, a travel-related GI illness, or a big diet change. The goal isn’t to “zero out” the signal; it’s to understand your baseline and notice meaningful departures from it. Research continues to refine how best to interpret thresholds, and cutoffs vary by assay, so results are most useful when viewed within your broader clinical picture and in collaboration with a healthcare professional.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

Making the host DNA result useful

When host DNA sits in an expected range for the platform, it tends to align with efficient digestion, intact barrier function, and low inflammatory signaling. When it is elevated, it may coincide with immune cell presence in stool and loss of beneficial barrier proteins — a pattern seen in infections and inflammatory conditions in clinical studies, though exact cutoffs differ by test. Importantly, red blood cells do not carry DNA; therefore, host DNA reflects epithelial and white blood cell contributions rather than occult blood alone. Abnormal findings are not a diagnosis; they are a prompt to consider context and, when appropriate, to pair with established markers (e.g., fecal calprotectin) or medical evaluation if symptoms persist.

Big picture: host DNA is most powerful when integrated with your symptoms, diet, medications, and other biomarkers over time. Side-by-side with microbiome data and inflammation panels, it helps personalize strategies aimed at supporting barrier integrity and calm immune tone. Assay differences, sample handling, and timing matter — so consistent collection methods and trend tracking enhance confidence in what the numbers mean for your day-to-day health.

Frequently Asked Questions

References

  1. Vincent C, Mehrotra S, Loo VG, Dewar K, Manges AR (2015). Excretion of host DNA in feces is associated with risk of Clostridium difficile infection. *Journal of Immunology Research*, *2015*, 246203. https://doi.org/10.1155/2015/246203
  2. Jiang P, Lai S, Wu S, Zhao XM, Chen WH (2020). Host DNA contents in fecal metagenomics as a biomarker for intestinal diseases and effective treatment. *BMC Genomics*, *21*(1), 348. https://doi.org/10.1186/s12864-020-6749-z
  3. Jovel J, Patterson J, Wang W, Hotte N, O'Keefe S, Mitchel T, Perry T, Kao D, Mason AL, Madsen KL, Wong GK (2016). Characterization of the gut microbiome using 16S or shotgun metagenomics. *Frontiers in Microbiology*, *7*, 459. https://doi.org/10.3389/fmicb.2016.00459
  4. Mann ER, Lam YK, Uhlig HH (2024). Short-chain fatty acids: Linking diet, the microbiome and immunity. *Nature Reviews Immunology*, *24*(8), 577-595. https://doi.org/10.1038/s41577-024-01014-8
  5. Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R (2019). Microbiome 101: Studying, analyzing, and interpreting gut microbiome data for clinicians. *Clinical Gastroenterology and Hepatology*, *17*(2), 218-230. https://doi.org/10.1016/j.cgh.2018.09.017

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey